

Narendranath Epperla

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6327310/narendranath-epperla-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149
papers

894
citations

16
h-index

23
g-index

167
ext. papers

1,275
ext. citations

3.8
avg, IF

4.59
L-index

#	Paper	IF	Citations
149	R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. <i>British Journal of Haematology</i> , 2018 , 180, 534-544	4.5	48
148	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017 , 92, 161-170	7.1	43
147	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. <i>Hematological Oncology</i> , 2017 , 35, 528-535	1.3	37
146	Medical Management of Pump-Related Thrombosis in Patients with Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis. <i>ASAIO Journal</i> , 2017 , 63, 373-385	3.6	35
145	Incidence and survival trends in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 181, 703-706	4.5	31
144	Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature. <i>BMC Neurology</i> , 2014 , 14, 200	3.1	27
143	Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. <i>SpringerPlus</i> , 2015 , 4, 455		25
142	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018 , 2, 933-940	7.8	23
141	Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. <i>British Journal of Haematology</i> , 2020 , 189, 1171-1181	4.5	22
140	Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. <i>Clinical Medicine and Research</i> , 2015 , 13, 32-5	1.4	21
139	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020 , 6, 1011-1018	13.4	19
138	C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. <i>Cancer</i> , 2017 , 123, 4411-4418	6.4	19
137	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021 , 137, 374-386	2.2	19
136	Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2017 , 10, 277-284	2.7	18
135	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018 , 124, 2306-2315	6.4	18
134	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 117	22.4	17
133	Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. <i>Transfusion</i> , 2017 , 57, 2775-2781	2.9	16

132	Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. <i>American Journal of Hematology</i> , 2016 , 91, E313-4	7.1	15
131	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 6	22.4	15
130	Emerging therapies in mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 79	22.4	14
129	Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. <i>Cancer Management and Research</i> , 2018 , 10, 615-624	3.6	13
128	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019 , 3, 1661-1669	7.8	13
127	A gene-based recessive diplotype exome scan discovers , a novel hepcidin-regulating iron-metabolism gene. <i>Blood</i> , 2019 , 133, 1888-1898	2.2	12
126	Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	12
125	Resistance mechanism for ibrutinib in marginal zone lymphoma. <i>Blood Advances</i> , 2019 , 3, 500-502	7.8	11
124	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. <i>Blood Advances</i> , 2020 , 4, 47-54	7.8	11
123	A rash diagnosis: Gemcitabine-associated pseudocellulitis. <i>Journal of Oncology Pharmacy Practice</i> , 2017 , 23, 157-160	1.7	10
122	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 427-433	4.5	10
121	Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. <i>American Journal of Hematology</i> , 2016 , 91, 644-6	7.1	10
120	Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 237-8	2.2	10
119	Apical hypertrophic cardiomyopathy presenting as recurrent unexplained syncope. <i>Clinical Medicine and Research</i> , 2012 , 10, 26-31	1.4	10
118	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. <i>Cancer</i> , 2019 , 125, 4417-4425	6.4	8
117	Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1393-404	4.4	8
116	Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
115	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2862-2870	1.9	8

114	Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1602-1604	4.4	8
113	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021 , 106, 1932-1942	6.6	8
112	Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 408-414	2	7
111	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 78-85	4.7	7
110	Difficult to swallow: warm autoimmune hemolytic anemia in a Jehovah@ Witness treated with hemoglobin concentrate complicated by achalasia. <i>Transfusion</i> , 2016 , 56, 1801-6	2.9	7
109	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019 , 134, 402-402	2.2	7
108	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3339-3350	12.9	7
107	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1129-1138	2.2	7
106	Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?. <i>Cancer Medicine</i> , 2020 , 9, 5519-5525	4.8	6
105	Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2016 , 175, 758	4.5	6
104	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 753-753	2.2	6
103	Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. <i>OncoTargets and Therapy</i> , 2021 , 14, 1797-1805	4.4	6
102	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020 , 126, 2279-2287	6.4	6
101	Appearances are Deceptive: Staphylococcus Superinfection of Clavicular Tuberculous Osteomyelitis. <i>Clinical Medicine and Research</i> , 2015 , 13, 85-8	1.4	5
100	Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?. <i>Annals of Hematology</i> , 2018 , 97, 1727-1729	3	5
99	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 983-988	4.7	5
98	Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report. <i>Diagnostic Pathology</i> , 2013 , 8, 192	3	5
97	Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017 , 92, E610-E611	7.1	5

96	Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. <i>Cancers</i> , 2021 , 13,	6.6	5
95	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021 , 7, 993-1003	13.4	5
94	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021 , 5, 2852-2862	7.8	5
93	Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 672-678	2	5
92	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 58-66		5
91	Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. <i>American Journal of Hematology</i> , 2018 , 93, 238-245	7.1	5
90	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 305-311.e2	2	4
89	Outcomes after stereotactic radiosurgery for CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2020 , 147, 465-476	4.8	4
88	An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis. <i>Skeletal Radiology</i> , 2014 , 43, 1313-8	2.7	4
87	ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole. <i>Clinical Medicine and Research</i> , 2013 , 11, 86-90	1.4	4
86	Non-cardiogenic pulmonary edema complicating electroconvulsive therapy: short review of the pathophysiology and diagnostic approach. <i>Clinical Medicine and Research</i> , 2012 , 10, 131-6	1.4	4
85	Early recognition is the key to success: pulseless electrical activity (PEA) as a manifestation of heparin-induced anaphylactoid reaction. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	4
84	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019 , 134, 1525-1525	2.2	4
83	Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2016 , 91, 1161-1164	7.1	4
82	Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). <i>American Journal of Hematology</i> , 2021 , 96, E123-E126	7.1	4
81	What is the optimal reduced-intensity conditioning regimen for patients with classical Hodgkin lymphoma undergoing allogeneic transplantation? - is there a one to use or avoid. <i>British Journal of Haematology</i> , 2020 , 190, 490-492	4.5	3
80	Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 47	4.2	3
79	Radiographic findings in Waldenström macroglobulinemia resembling fibrogenesis imperfecta ossium (FIO): a case report. <i>Skeletal Radiology</i> , 2014 , 43, 381-5	2.7	3

78	Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. <i>Bone Marrow Transplantation</i> , 2017 , 52, 147-150	4.4	3
77	Unprovoked deep venous thrombosis in a young adult associated with membranous obstruction of inferior vena cava. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	3
76	Sweet's syndrome: one disease, multiple faces. <i>Clinical Medicine and Research</i> , 2011 , 9, 134-6	1.4	3
75	Brain abscesses complicating acute pneumococcal meningitis during etanercept therapy. <i>Clinical Medicine and Research</i> , 2012 , 10, 230-5	1.4	3
74	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019 , 134, 397-397	2.2	3
73	Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. <i>Blood</i> , 2016 , 128, 1785-1785	2.2	3
72	Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2021 , 138, 93-93 ²		3
71	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020 , 26, 6187-6195	12.9	3
70	Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 104	22.4	3
69	Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 95-102	2	3
68	Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. <i>Blood</i> , 2020 , 136, 2-3	2.2	2
67	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021 , 138, 884-884	2.2	2
66	Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial. <i>Blood</i> , 2019 , 134, 2853-2853	2.2	2
65	Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States. <i>American Journal of Hematology</i> , 2021 , 96, 816-822	7.1	2
64	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019 , 60, 940-946	1.9	2
63	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021 , 96, 1374-1384	7.1	2
62	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021 , 195, 757-763	4.5	2
61	A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. <i>Current Hematologic Malignancy Reports</i> , 2021 , 16, 19-24	4.4	2

60	Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2021 , 2021, 247-253	3.1	2
59	An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. <i>BMC Hematology</i> , 2015 , 15, 7	2.5	1
58	Thrombotic Thrombocytopenic Purpura and the Hemolytic Uremic Syndromes 2018 , 1984-2000		1
57	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020 , 136, 49-50	2.2	1
56	Relative Survival of Patients with Nodal Marginal Zone Lymphoma in the United States: A Population-Based Analysis. <i>Blood</i> , 2020 , 136, 5-6	2.2	1
55	Recent Survival Trends in Diffuse Large B-Cell Lymphoma (DLBCL)-Did We Make Any Progress Beyond Rituximab?. <i>Blood</i> , 2018 , 132, 4828-4828	2.2	1
54	Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 4185-4185	2.2	1
53	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 3997-3997	2.2	1
52	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 3483-3483	2.2	1
51	Outcomes of Grade 3A Follicular Lymphoma: Best Treated As Aggressive or Indolent Lymphoma?. <i>Blood</i> , 2016 , 128, 5328-5328	2.2	1
50	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. <i>Blood</i> , 2021 , 138, 455-455	2.2	1
49	Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. <i>World Journal of Transplantation</i> , 2015 , 5, 81-8	2.3	1
48	Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment. <i>Blood</i> , 2018 , 132, 2305-2305	2.2	1
47	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 26, 100-109		1
46	NCMP-12. RAPIDLY PROGRESSIVE NEUROPATHIES AS THE SOLE PRESENTATION OF NEUROLYMPHOMATOSIS. <i>Neuro-Oncology</i> , 2020 , 22, ii125-ii125	1	1
45	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021 , 107, 301-310	3.8	1
44	MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR). <i>Hematological Oncology</i> , 2019 , 37, 405-407	1.3	1
43	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. <i>Bone Marrow Transplantation</i> , 2019 , 54, 913-916	4.4	1

42	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. <i>Hematological Oncology</i> , 2021 , 39, 473-482	1.3	1
41	Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States. <i>Cancer Medicine</i> , 2021 , 10, 7330-7338	4.8	1
40	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020 , 136, 35-36	2.2	1
39	A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 29-29	2.2	0
38	Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 4082-4082	2.2	0
37	Treatment-Related Cardiovascular Outcomes in Patients with Symptomatic Subclavian Artery Stenosis. <i>Cureus</i> , 2017 , 9, e1262	1.2	0
36	How I incorporate novel agents into the treatment of classical Hodgkin lymphoma. <i>Blood</i> , 2021 , 138, 520-530	2.2	0
35	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021 , 5, 5179-5189	7.8	0
34	An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2016 , 47, 206-9	1.6	
33	Indolent lymphomas 2017 , 140-150		
32	Mantle cell lymphoma 2017 , 164-178		
31	Chemotherapy: Response and Survival Data #99. <i>Journal of Palliative Medicine</i> , 2016 , 19, 1011	2.2	
30	1174. <i>Critical Care Medicine</i> , 2013 , 41, A298-A299	1.4	
29	Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis. <i>Blood</i> , 2020 , 136, 31-32	2.2	
28	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. <i>Blood</i> , 2020 , 136, 24-26	2.2	
27	Racial and Ethnic Disparities in the Survival of Patients with Indolent Non-Hodgkin Lymphoma in the United States: A Population-Based Analysis. <i>Blood</i> , 2020 , 136, 3-3	2.2	
26	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. <i>Blood</i> , 2020 , 136, 4-6	2.2	
25	Decreased Lymphoma-Specific Mortality in Patients with Splenic Marginal Zone Lymphoma in the United States. <i>Blood</i> , 2020 , 136, 9-9	2.2	

24	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020 , 136, 46-49	2.2
23	Impact of Primary Site and Era of Diagnosis on Mortality in Patients with Extranodal Marginal Zone Lymphoma in the United States: A Population-Based Study. <i>Blood</i> , 2020 , 136, 44-44	2.2
22	Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis. <i>Blood</i> , 2021 , 138, 1451-1451	2.2
21	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021 , 138, 532-532	2.2
20	Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study. <i>Blood</i> , 2021 , 138, 1425-1425	2.2
19	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018 , 132, 4153-4153	2.2
18	Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018 , 132, 2918-2918 ^{2,2}	2.2
17	Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2018 , 132, 969-969	2.2
16	Adverse Events Among Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogs in the United States. <i>Blood</i> , 2018 , 132, 4833-4833	2.2
15	Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment. <i>Blood</i> , 2018 , 132, 4143-4143	2.2
14	HSR19-086: Healthcare Costs and Resource Utilization Associated With Adverse Events Among Hairy Cell Leukemia Patients Treated With Purine Nucleoside Analogs. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, HSR19-086	7.3
13	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 5891-5891	2.2
12	Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. <i>Blood</i> , 2019 , 134, 1554-1554	2.2
11	Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20064-e20064	2.2
10	Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8043-8043	2.2
9	Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015 , 126, 4360-4360	2.2
8	Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015 , 126, 3169-3169 ^{2,2}	2.2
7	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. <i>Blood</i> , 2015 , 126, 2711-2711	2.2

6	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. <i>Blood</i> , 2016 , 128, 513-513	2.2
5	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. <i>Blood</i> , 2016 , 128, 103-103	2.2
4	MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7541-7541	2.2
3	PHASE I DOSE-ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH-RISK NON-HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS. <i>Hematological Oncology</i> , 2019 , 37, 528-529	1.3
2	OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY. <i>Hematological Oncology</i> , 2019 , 37, 408-410	1.3
1	Racial differences in the survival of mantle cell lymphoma patients in the United States.. <i>Hematological Oncology</i> , 2022 ,	1.3